Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

doi:10.4251/wjgo.v10.i12.505

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9390)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

522

WORD

200

HTML

4061

Figures (1-1)

311

Tables (1-5)

262

Sum=5356

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

571

Download

1213

Sum=1784

Publishing Process of This Article

Item

Count

Browse

961

Download

1289

Sum=2250

Dec 15, 2018 (publication date) through Dec 19, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Oncol. Dec 15, 2018; 10(12): 505-515
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.505

Open in New Tab Full Size Figure Download Figure

Figure 1 Kaplan-Meier analysis of survival data. A: The estimated median progression-free survival was 5.8 mo (95%CI: 3.7-7.9); B: The estimated median overall survival was 9.0 mo (95%CI: 6.4-11.6).

Citation: Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515
URL: https://www.wjgnet.com/1948-5204/full/v10/i12/505.htm
DOI: https://dx.doi.org/10.4251/wjgo.v10.i12.505